XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2025
Dec. 31, 2024
Current Assets:    
Cash and cash equivalents $ 672 $ 675
Accounts receivable (net of allowance for doubtful accounts of $12 in 2025 and $14 in 2024) 1,484 1,358
Inventories (excludes inventories of $247 in 2025 and $215 in 2024 classified in Other assets) 1,488 1,321
Other current assets 1,056 994
Total Current Assets 4,700 4,348
Property, plant and equipment, net 1,290 1,168
Goodwill 4,680 4,680
Intangibles, net 1,340 1,414
Other assets 1,542 1,491
Total Assets 13,552 13,101
Current Liabilities:    
Current portion of long-term debt and short-term borrowings 45 20
Trade accounts payable 1,074 1,153
Accrued and other current liabilities 1,444 1,411
Income taxes payable 116 134
Total Current Liabilities 2,679 2,718
Long-term debt 8,783 8,860
Deferred income taxes 62 74
Other noncurrent liabilities 1,122 977
Total Liabilities 12,646 12,629
Contingencies (Note 15)
Organon & Co. Stockholders’ Equity:    
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 259,983 in 2025 and 257,799 in 2024 3 3
Additional paid-in capital 159 108
Retained earnings 1,318 1,010
Accumulated other comprehensive loss (574) (649)
Total Stockholders’ Equity 906 472
Total Liabilities and Stockholders’ Equity $ 13,552 $ 13,101